China's biotech advancements attract global pharmaceutical partnerships

China's biotech sector is rapidly advancing, attracting major global pharmaceutical companies. AbbVie, AstraZeneca, and Merck have all signed significant deals with Chinese firms for innovative treatments, marking a shift in the global pharmaceutical landscape. Indian drugmakers are also collaborating with Chinese companies, with Mankind Pharma and Dr. Reddy’s Labs forming partnerships to bring new cancer treatments to India. This reflects a growing recognition of the need for innovation in India's pharmaceutical industry. China's success stems from strong investments in research and a supportive regulatory environment, allowing for faster clinical trials. In contrast, India faces bureaucratic challenges that hinder its progress in drug innovation.